Bambusa Therapeutics raises $168.9 million in biotech IPO priced at $16
As seen on the 24/7 Wall St. homepage on October 30, 2026.
Bambusa Therapeutics prices IPO at $16, raising $168.9 million
Bambusa Therapeutics priced at $16 a share, pulling in roughly $168.9 million with BofA, Evercore ISI, UBS and Cantor running the book. A deal that size clearing in biotech signals the IPO window is open wider than it has been all year.
Continue ReadingShow less
Bambusa Therapeutics priced its initial public offering at $16 a share to bring in roughly $168.9 million, with BofA, Evercore ISI, UBS, and Cantor as bookrunners. That syndicate signals institutional demand broad enough to attract multiple bulge-bracket names.
A deal of nearly $169 million clearing in biotech is notable on its own terms. Large biotech IPOs require investors to make long-duration bets on science that is years from generating revenue, so a raise of this size getting done cleanly at a firm price reflects genuine risk appetite.
Sponsored
The offering price landing at exactly $16 with no disclosed range suggests the final terms were set with conviction. That kind of clean pricing is one of the cleaner signals that bookrunners came away with more demand than they strictly needed.
A deal this size clearing in biotech signals the IPO window is open wider than it has been all year, which matters for any company currently weighing whether to file or wait. Conditions that allow one sizable biotech to price cleanly tend to encourage others toward the market.